Biogen to acquire ophthalmology gene therapy play Nightstar

Gene therapy platforms continue to capture the interest of large biopharma, with Biogen the latest to announce a deal. The bellwether said early Monday that it will acquire ophthalmology gene therapy company Nightstar for $877 million, marking the second major gene therapy acquisition in the past week.

On Feb. 25, Roche announced it would acquire gene therapy play Spark Therapeutics Inc. (NASDAQ:ONCE) for $4.8 billion (see "Spark Gives Roche Beachhead in Gene Therapy")...